Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17609 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Bridgette Wilson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences, King's College London, London, UK. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Gastrointestinal Microbiome. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: King’s College London.
Abstract (Originalsprache)
Background
The low FODMAP diet (LFD) leads to clinical response in 50%–80% of patients with irritable bowel syndrome (IBS). It is unclear why only some patients respond.
Aims
To determine if differences in baseline faecal microbiota or faecal and urine metabolite profiles may separate clinical responders to the diet from non‐responders allowing predictive algorithms to be proposed.
Methods
We recruited adults fulfilling Rome III criteria for IBS to a blinded randomised controlled trial. Patients were randomised to sham diet with a placebo supplement (control) or LFD supplemented with either placebo (LFD) or 1.8 g/d B‐galactooligosaccharide (LFD/B‐GOS), for 4 weeks. Clinical response was defined as adequate symptom relief at 4 weeks after the intervention (global symptom question). Differences between responders and non‐responders in faecal microbiota (FISH, 16S rRNA sequencing) and faecal (gas–liquid chromatography, gas‐chromatography mass‐spectrometry) and urine ( 1 H NMR) metabolites were analysed.
Results
At 4 weeks, clinical response differed across the 3groups with adequate symptom relief of 30% (7/23) in controls, 50% (11/22) in the LFD group and 67% (16/24) in the LFD/B‐GOS group ( p = 0.048). In the control and the LFD/B‐GOS groups, microbiota and metabolites did not separate responders from non‐responders. In the LFD group, higher baseline faecal propionate (sensitivity 91%, specificity 89%) and cyclohexanecarboxylic acid esters (sensitivity 80%, specificity 78%), and urine metabolite profile ( Q 2 0.296 vs. randomised −0.175) predicted clinical response.
Conclusions
Baseline faecal and urine metabolites may predict response to the LFD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences, King's College London, London, UK.
- Department of Nutrition and Dietetics, Guys and St Thomas' NHS Foundation Trust, London, UK.
- King's College London, Institute of Pharmaceutical Science, London, UK.
- University of Liverpool, Institute of Systems, Molecular and Integrative Biology, Liverpool, UK.
- Department of Gastroenterology, Guys and St Thomas' NHS Foundation Trust, London, UK.
- School of Immunology and Microbial Sciences, King's College London, London, UK.
ORCID-Profile: Peter M Irving, Chris Probert, Kevin Whelan
Förderung
- King’s College London
Zitieren
APA
Wilson, B., Kanno, T., Slater, R., Rossi, M., Irving, P. M., Lomer, M. C., Probert, C., Mason, A. J., & Whelan, K. (2023). Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17609
Vancouver
Wilson B, Kanno T, Slater R, Rossi M, Irving PM, Lomer MC, et al. Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17609
BibTeX
@article{Wilson2023,
author = {Wilson, Bridgette and Kanno, Tokuwa and Slater, Rachael and Rossi, Megan and Irving, Peter M and Lomer, Miranda C and Probert, Chris and Mason, A James and Whelan, Kevin},
title = {Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndrome},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17609}
}
EUVIMED